Review ArticleNoncoding RNAs in Atrial Fibrillation Current Status and ProspectZhou, Dongchen MD; Yang, Kun; Hu, Jingjing; Shi, Jiaran; Hu, Xiaosheng MDAuthor Information Department of Cardiology, The First Affiliated Hospital, Medical School of Zhejiang University, Zhejiang Province, China. Reprints: Xiaosheng Hu, MD, Department of Cardiology, The First Affiliated Hospital, Medical School of Zhejiang University, Zhejiang Province 310000, China (e-mail: firstname.lastname@example.org). Supported by the Zhejiang provincial medical and health science and technology project, China (grant numbers 2019KY071). The authors report no conflicts of interest. Received February 13, 2019 Accepted September 16, 2019 Journal of Cardiovascular Pharmacology: January 2020 - Volume 75 - Issue 1 - p 10–17 doi: 10.1097/FJC.0000000000000762 Buy Metrics Abstract Abstract: Atrial fibrillation (AF) is an important cause of cardiovascular morbidity and mortality. Current therapies for AF are ineffective, mainly due to incomplete understanding of the pathogenesis of AF. Atrial remodeling contributes to the occurrence and progression of AF, but molecular mechanisms underlying AF remain unclear. Noncoding RNAs, including microRNAs, long noncoding RNAs and circular RNAs, are now considered to play an important role in the pathophysiology of AF. In this review, we summarize recent evidence supporting the role of noncoding RNAs in AF and highlight their diagnostic and prognostic applications as potential biomarkers and therapeutic strategies. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.